Navigation Links
Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets
Date:8/11/2009

PRINCETON, N.J., Aug. 11 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base). The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Imitrex(R)* by GlaxoSmithKline. Total annual market sales for Sumatriptan Succinate 25 mg and 50 mg tablets were $379 million (IMS - MAT: June 2009) which is indicated for the acute treatment of migraine attacks with or without aura in adults.

"We are pleased to receive this final approval for Sumatriptan Succinate Tablets 25 mg and 50 mg in addition to the 100 mg that was previously approved. This FDA approval represents the sixth such authorization to commercialize product to be granted by the agency so far in 2009. This product will be launched immediately to all classes of trade and further expands our product portfolio of affordable generic product formulations, that will be of benefit to patients, healthcare professionals and the U.S. healthcare system," according to Bill Winter, Vice President, Trade Sales, North America.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets
2. Press Statement Issued by Ranbaxy Laboratories Limited
3. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
4. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
5. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
6. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
7. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
8. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
9. Ranbaxy Receives Tentative Approval For Valsartan Tablets
10. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
11. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... December 19, 2014 Consilium Staffing, ... the AMSUS Society for Federal Health Professionals annual ... tenens industry to military and federal healthcare providers. ... National Veterans Small Business Engagement (NVSBE) conference last ... to be a vital solution in addressing our ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- The tragic death from "rat-bite ... carried by the pet rodents, according to a report from ... fever is a rare but potentially fatal illness that should ... and when a history of rodent exposure is reported," said ... Epidemic Intelligence Service. The case outlined in the report ...
(Date:12/19/2014)... analogue eye drops -- a common form of glaucoma ... in patients with the eye disease, a new study ... the Moorfields Eye Hospital and UCL Institute of Ophthalmology ... newly diagnosed with open-angle glaucoma -- the most common ... causes of blindness. About 45 million people worldwide ...
(Date:12/17/2014)... Marlborough, Mass. (PRWEB) December 17, 2014 ... College of Osteopathic Medicine (ACOM), which welcomed its ... Virtual Desktop Infrastructure (VDI) to seamlessly support bring ... learning – and teaching – experience. The solution, ... Citrix NetScaler , Dell server and storage ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... comes to mating, male chimpanzees have the opposite taste when ... species, human beings, //according to a study published Tuesday. ... older females and turn up their nose at younger ones. ... on studies of a group of Kanyawara chimpanzees in Uganda's ...
... a mother of two children died of breast cancer due to ... //Dr.John Philip was not qualified to read mammograms according to the ... Jackson. ,The woman who is identified as Mrs. A, ... her that she was normal. When she went for a second ...
... Centre at Canada's University //of British Columbia conducted a ... Alzheimer’s disease. , ,During the study, the researchers ... low-oxygen levels for about 16 hours a day, which ... normal levels of oxygen. ,After a month ...
... that sex does not increase the chances of heart attack, ... to movie mythology. //The study reported that ‘while sex causes ... could lift the likelihood 20-folds’. ,The review by ... analyse triggers for heart attacks, including sexual activity, cocaine use, ...
... US government has awarded three more contracts to buy and ... 2.7 million people, at a cost of $199.45 million. ... (HHS) the contracts are for a total of 5.3 million ... to GlaxoSmithKline (GSK) for 800,000 doses, $40.95 million to Novartis ...
... who suffer from allergy to grass pollen will now ... introduced, tablet based //vaccine named Grazax? is being marketed ... treatment. ,Allergy from grass pollen prominently disrupts quality ... social interaction severely .Statistics reveal that over 45 million ...
Cached Medicine News:Health News:US Orders More H5N1 vaccine 2
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... For complete orthopedic trauma procedures. ... system, the orthopedic trauma table top ... for easy patient positioning and provides ... key trauma procedures: hip pinnings; femur, ...
... The EXOGEN 2000+ device provides a ... nonunion or the acceleration of fresh ... home for 20 minutes daily, or ... your physician determines your fracture to ...
... cannulated interference screws have a ... screw divergence. Screws are available ... lengths. Screws are supplied sterile, ... and 9mm dia. (screws are ...
Medicine Products: